This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novartis AG Management Discusses Q2 2012 Results - Earnings Call Transcript

Novartis AG (NVS)

Q2 2012 Earnings Call

July 19, 2012 8:00 am ET


Joseph Jimenez - Chief Executive Officer

Susanne Schaffert - Head of Oncology - Novartis Pharma Germany

Jonathan Symonds - Chief Financial Officer

David Epstein - Division Head of Novartis Pharmaceuticals

Brian Mcnamara - Division Head of Novartis Otc

Kevin J. Buehler - President, Chief Executive Officer, and Chairman

Andrin Oswald - Division Head of Vaccines & Diagnostics

Jeffrey George - Division Head of Sandoz and Member of Executive Committee


Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Alistair D. Campbell - Berenberg Bank, Research Division

Alexandra Hauber - JP Morgan Chase & Co, Research Division

Matthew Weston - Crédit Suisse AG, Research Division

Naresh Chouhan - Liberum Capital Limited, Research Division

Michael Leuchten - Barclays Capital, Research Division

Andrew C. Weiss - Bank Vontobel AG, Research Division

Seamus Fernandez - Leerink Swann LLC, Research Division

Florent Cespedes - Exane BNP Paribas, Research Division

Andrew S. Baum - Citigroup Inc, Research Division

Peter Verdult - Morgan Stanley, Research Division

Florian Gaiser



Good morning and good afternoon, and welcome to the Novartis Q2 Half Year 2012 Results Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded. [Operator Instructions] With that, I would like to hand over to Mr. Joe Jimenez, CEO of Novartis. Please go ahead, sir.

Joseph Jimenez

Thank you. I'd like to welcome everyone to our second quarter and first-half conference call. With me today on the Novartis end are Jon Symonds, the CFO; David Epstein, Head of Pharma; we have all of the division heads, and we have Tim Wright, who is the Head of Pharma Development, with us. So before we begin, I'd like to ask Susanne Schaffert to read the Safe Harbor statement.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs